This paper analyzes the case from Harvard called "Abegenix and the XenoMouse" about how the Abegenix company must decide what to do about developing a product to eliminate cancer from a patent it owns, whether to develop the product itself, partner with a company and share in the expenses as well as the profits, or license the technology and take a royalty.
